Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have earned a consensus recommendation of “Hold” from the nine analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $2.20.
Separately, Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th.
Shares of AVEO remained flat at $$0.67 on Monday. 1,025,900 shares of the company were exchanged, compared to its average volume of 2,485,013. The company has a quick ratio of 1.39, a current ratio of 2.21 and a debt-to-equity ratio of 6.84. AVEO Pharmaceuticals has a 12 month low of $0.49 and a 12 month high of $3.59. The firm has a market cap of $107.70 million, a PE ratio of -3.53 and a beta of 0.78. The company has a fifty day moving average of $0.68 and a two-hundred day moving average of $0.74.
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.04. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.78 million. AVEO Pharmaceuticals had a negative net margin of 46.69% and a negative return on equity of 50.69%. Equities research analysts forecast that AVEO Pharmaceuticals will post -0.08 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the business. HCR Wealth Advisors purchased a new stake in AVEO Pharmaceuticals in the 1st quarter valued at about $28,000. Cetera Advisor Networks LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter valued at about $38,000. Excalibur Management Corp increased its stake in AVEO Pharmaceuticals by 363.6% in the 1st quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 40,000 shares during the last quarter. SG Americas Securities LLC purchased a new stake in AVEO Pharmaceuticals in the 1st quarter valued at about $50,000. Finally, Jane Street Group LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter valued at about $98,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
See Also: What are catch-up contributions?
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.